EICHORCondition: Nonalcoholic Steatohepatitis (NASH) · Sponsor: GlaxoSmithKline
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Central Research Associates | Birmingham, Alabama, United States | — |
| Arizona Liver Health | Chandler, Arizona, United States | — |
| Arizona Liver Health | Peoria, Arizona, United States | — |
| Arizona Liver Health | Tucson, Arizona, United States | — |
| Liver Institute PPLC | Tucson, Arizona, United States | — |
| QLMC | Tucson, Arizona, United States | — |
| Alliance Research Institute | Canoga Park, California, United States | — |
| Ark Clinical Research | Fountain Valley, California, United States | — |
| Fresno Clinical Research Center | Fresno, California, United States | — |
| Catalina Research Institute | Montclair, California, United States | — |
| Knowledge Research Center | Orange, California, United States | — |
| FOMAT Medical Research | Oxnard, California, United States | — |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04880031